The FDA's Drugs@FDA database lists a supplement dated 14 September 2026 to abbreviated new drug application ANDA205080, a generic itraconazole held by Amneal. The record carries no detail of what the supplement changes.
Supplements to generic applications are routine and usually concern manufacturing, labelling alignment with the reference product or packaging. Nothing in the record indicates a new indication, a safety communication or a supply problem.
Itraconazole remains important for endemic mycoses and chronic pulmonary aspergillosis, and its variable absorption and drug interactions are the practical issues for prescribers — unchanged by this record. It is a US generic application and has no direct bearing on products sold in India.
- No change to itraconazole prescribing follows from this record.
- Itraconazole capsule absorption needs food and gastric acid; avoid co-prescribing PPIs where possible.
- Check interactions before starting — it is a strong CYP3A4 inhibitor.
- Monitor levels in serious infection where therapeutic drug monitoring is available.
Why it matters
It is the only regulatory activity on this desk today, and it needs no action.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free